In addition, a recent report suggests that patients with elevated c-MYC expression show enhanced sensitivity to proteasome inhibitors in relapsed/refractory multiple myeloma (69), indicating that c-MYC might be a clinically relevant target of proteasome inhibition. Here, MYC is linked to plasma cell myeloma.